Advanced Search

 

Study ID Status Title Patient Level Data
KG2110375 Completed A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
KG219017 Completed A double blind, randomized, placebo controlled, single-dose escalation, first-time-in-human crossover study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of ascending doses of GSK189075A in healthy subjects and in subjects with type 2 diabetes mellitus
KGI107465 Completed A double-blind, randomized, single ascending dose escalation, placebo-controlled, crossover study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK189075 administered to subjects with type 1 diabetes mellitus
KGO105858 Completed A Double-Blind, Randomized, Placebo-controlled Study to Evaluate Weight Loss, Safety, Tolerability and Pharmacokinetics in Obese Subjects Following 12-Week Dosing of GW869682, an SGLT2 inhibitor
KGW108201 Completed An exploratory study to evaluate weight loss, body composition changes, food intake and urine glucose excretion in healthy obese subjects over 8 weeks of dosing with GSK189075, GW869682 versus placebo
KGW111057 Completed An open-label, randomized, single dose, crossover study to assess the pharmacokinetics, pharmacodynamics, safety, and tolerability of modified release formulations of GSK189075 in healthy volunteers
KGW111083 Completed A double-blind, randomized, 6-sequence, 3-period crossover drug-drug interaction study to evaluate the pharmacokinetics of WELLBUTRIN SR (bupropion) and GSK189075 when co-administered or administered alone in healthy male volunteers
KSP10003 Completed A Phase I, Open-Label Study of SB-715992 in Combination with Docetaxel in Patients with Advanced Solid Tumors.
KSP10004 Completed A Phase I, Open-Label, Dose-Escalation Study of the Safety and Tolerability of Ispinesib in Combination with Capecitabine on an Every 21-Day Schedule in Subjects with Advanced Solid Tumors
KSP10014 Completed A Phase I, Open-Label, Dose-Escalation Study of the Safety and Tolerability of Ispinesib in Combination with Carboplatin on an Every 21-Day Schedule in Subjects with Advanced Solid Tumors.
KSP20001 Completed Phase II, Open Label Study of Ispinesib in Subjects with Advanced or Metastatic Breast Cancer
KSP20007 Completed A Phase II, Open-Label Study of Ispinesib in Subjects with Locally Advanced or Metastatic Platinum-Refractory or Platinum-Relapsed Non-Small Cell Lung Cancer (NSCLC)
KSP20008 Completed A Phase II, Open-Label Study of Ispinesib in Subjects with Platinum/Taxane-Refractory or Resistant Relapsed Ovarian Cancer
L4665-03 Completed A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients with Immune Thrombocytopenic Purpura (ITP) with an Open Label Extension
LAC103842 Completed An open label, multi-centre, single arm phase IV study to evaluate the antihypertensive effect of Lacidipine in mild to moderate essential hypertension patients with Type 2 diabetes in Korea
LAM100034 Completed A Multicenter, Double-Blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-release Adjunctive Therapy in Subjects with Partial Seizures Study Listed on ClinicalStudyDataRequest.com
LAM100036 Completed A Multicenter, Double-blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-Release Adjunctive Therapy in Patients with Primary Generalized Tonic-Clonic Seizures Study Listed on ClinicalStudyDataRequest.com
LAM100118 Completed An Open-label Evaluation of LAMICTAL (lamotrigine) Monotherapy for the Treatment of Newly-diagnosed Typical Absence Seizures in Children and Adolescents Study Listed on ClinicalStudyDataRequest.com
LAM105379 Completed A pivotal single-dose randomised, parallel-group, open-label study to demonstrate bioequivalence of 300mg lamotrigine XR relative to 100mg + 200mg lamotrigine XR and to demonstrate lack of food effect on 300mg lamotrigine XR in healthy male and female volunteers Study Listed on ClinicalStudyDataRequest.com
LAM107844 Completed Clinical Evaluation of BW430C in Epilepsy<Phase III Study>
LAM20006 Completed A Double-Blind, Placebo-Controlled, Add-On Clinical Trial of the Safety, Pharmacokinetics and Efficacy of Lamictal in Pediatric Age Subjects (1-24 months) Study Listed on ClinicalStudyDataRequest.com
LAM20007 Completed An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive subjects (1-24 months of age) Study Listed on ClinicalStudyDataRequest.com
LAM-2003-01 Recruiting Validation Of Qolie-10 For Epilepsy, Comparison Of Quality Of Life In Patients Treated With Lamotrigine Or Valproic Acid
LAM30055 Completed A Multicenter, Double-Blind, Randomized Conversion to Monotherapy Comparison of Two Doses of Lamotrigine for the Treatment of Partial Seizures Study Listed on ClinicalStudyDataRequest.com
LAM40013 Completed A Multicenter, Open-Label Conversion of Valproate Monotherapy to Lamotrigine Monotherapy in Patients with Epilepsy Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.